Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03343054
What this trial is testing

Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Who this might be right for
NeoplasmsBreast Neoplasms
Pfizer 28
Early research (Phase 1)Study completedNCT01085422
What this trial is testing

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
AbbVie (prior sponsor, Abbott) 35
Very early researchStudy completedNCT05320757
What this trial is testing

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

Who this might be right for
Endometrial Cancer
The University of Hong Kong 20
Testing effectiveness (Phase 2)Ended earlyNCT04999605
What this trial is testing

AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

Who this might be right for
Ovarian NeoplasmsRecurrent Ovarian CarcinomaRelapsed Ovarian Cancer+1 more
Akeso 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT03672773
What this trial is testing

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Who this might be right for
Recurrent Extensive Stage Small Cell Lung CarcinomaRefractory Extensive Stage Small Cell Lung Carcinoma
Jonsson Comprehensive Cancer Center 35
Testing effectiveness (Phase 2)Ended earlyNCT03330405
What this trial is testing

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Who this might be right for
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Pfizer 223
Testing effectiveness (Phase 2)UnknownNCT05327621
What this trial is testing

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Sun Yat-sen University 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT03579316
What this trial is testing

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
M.D. Anderson Cancer Center 96
Large-scale testing (Phase 3)Active Not RecruitingNCT02655016
What this trial is testing

Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 733
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05232006
What this trial is testing

PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers

Who this might be right for
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
Assistance Publique - Hôpitaux de Paris 12
Early research (Phase 1)Study completedNCT01445522
What this trial is testing

ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer

Who this might be right for
NeoplasmsLymphoma
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Looking for participantsNCT04090567
What this trial is testing

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 60
Early research (Phase 1)Study completedNCT01445418
What this trial is testing

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Who this might be right for
Breast CancerOvarian Cancer
National Cancer Institute (NCI) 103
Testing effectiveness (Phase 2)WithdrawnNCT06120972
What this trial is testing

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Who this might be right for
Ovarian Cancer
Alexander B Olawaiye, MD
Not applicableStudy completedNCT02721537
What this trial is testing

Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes

Who this might be right for
Concussion, Mild
Mayo Clinic 30
Testing effectiveness (Phase 2)Study completedNCT00494234
What this trial is testing

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
AstraZeneca 54
Testing effectiveness (Phase 2)Looking for participantsNCT07340164
What this trial is testing

Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy

Who this might be right for
Ovarian CancerOvarian Carcinoma, RecurrentOvarian Cancer Metastatic Recurrent+1 more
Yonsei University 116
Large-scale testing (Phase 3)Study completedNCT02184195
What this trial is testing

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Who this might be right for
Germline BRCA1/2 Mutations andMetastatic Adenocarcinoma of the Pancreas
AstraZeneca 154
Testing effectiveness (Phase 2)UnknownNCT06055166
What this trial is testing

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

Who this might be right for
PARP Inhibitor for Esophageal Squamous Cell Carcinoma
Chongqing University Cancer Hospital 120
Testing effectiveness (Phase 2)Study completedNCT01989546
What this trial is testing

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Who this might be right for
Advanced Ovarian CancerPrimary Peritoneal CancerAdvanced Breast Cancer+1 more
National Cancer Institute (NCI) 9
Next Page